This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Geron's (GERN) Q4 Loss In Line, Revenues Beat, Stock Up
by Zacks Equity Research
Geron (GERN) posts loss in line with the estimate in fourth-quarter 2018 but beats on revenues. Operating expenses increase on a year-over-year basis.
How to Invest in Woman-Led Companies With ETFs & Stocks
by Sweta Killa
We have highlighted some top-ranked stocks that are headed by female CEOs and have massive upside potential in the coming years. Also, there are a three ETFs offering broad exposure to women-led companies.
Allergan's Depression Candidate Fails in Studies, Stock Down
by Zacks Equity Research
Allergan's (AGN) three acute pivotal studies on depression candidate, rapastinel, fail to meet their primary endpoint. Stocks declines 1.9%
Can Smart Beta & Factor ETFs Beat the Market?
by Neena Mishra
Here is what investors need to know about smart beta and factor strategies that combine the best aspects of active and passive investing.
J&J's (JNJ) Nasal Spray Spravato Gets FDA Nod for Depression
by Zacks Equity Research
J&J (JNJ) gets FDA nod for its new nasal spray, Spravato (esketamine) for treatment-resistant depression
The Zacks Analyst Blog Highlights: Facebook, Johnson & Johnson, JPMorgan, Sun Life and Evergy
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Facebook, Johnson & Johnson, JPMorgan, Sun Life and Evergy
Pacira (PCRX) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Pacira (PCRX) impresses investors with both earnings and revenue beat in the fourth quarter.
Pharma Stock Roundup: Roche to Buy ONCE, Lawmakers Grill CEOs Over High Drug Prices
by Zacks Equity Research
Roche (RHHBY) to buy Spark Therapeutics for $4.8 billion. Executives of big pharma companies face senators' questions over high drug prices.
Top Stock Reports for Facebook, Johnson & Johnson & JPMorgan
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Facebook (FB), Johnson & Johnson (JNJ) and JPMorgan (JPM).
Perrigo (PRGO) Q4 Earnings Miss, Sales Beat, Stock Down
by Zacks Equity Research
Perrigo (PRGO) reports wider loss in fourth-quarter 2018. However, sales were marginally higher. Challenges in the Rx segment continues to hurt the top line.
Theravance (TBPH) Q4 Loss Narrows, Revenues Beat Estimates
by Zacks Equity Research
Theravance Biopharma (TBPH) incurs narrower-than-expected loss in Q4. The top line surpasses estimates.
AbbVie Extends Deal With Voyager to Make Parkinson's Drugs
by Zacks Equity Research
AbbVie (ABBV) expands its collaboration with Voyager Therapeutics to develop potential vectorized antibodies for Parkinson's disease (PD) and other synucleinopathies.
What's in the Cards for Perrigo (PRGO) This Earnings Season?
by Zacks Equity Research
Perrigo (PRGO) is focused on Consumer Healthcare Americas segment. Let's see if it aids the company's results in the soon-to-be reported quarter.
Why Is Johnson & Johnson (JNJ) Up 5.9% Since Last Earnings Report?
by Zacks Equity Research
Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Johnson & Johnson (JNJ) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Johnson & Johnson (JNJ) closed at $136.35, marking a +0.49% move from the previous day.
Johnson & Johnson (JNJ) to Acquire Auris Health for $3.4B
by Zacks Equity Research
Johnson & Johnson (JNJ) entered into a definitive agreement to acquire Auris Health, Inc., a developer of robotic technologies focused on lung cancer, for approximately $3.4 billion in cash.
J&J's (JNJ) Depression Treatment Gets FDA Committee's Nod
by Zacks Equity Research
J&J (JNJ) gets FDA advisory committee's positive recommendation for its investigational nasal spray, Spravato (esketamine) for treatment-resistant depression in adults.
Winners & Losers from Trump's State of the Union Address
by Swarup Gupta
While pharma majors could face greater scrutiny on drug pricing, defense, infrastructure and energy are likely to emerge as big winners.
Merck (MRK) Beats on Q4 Earnings & Sales as Keytruda Shines
by Zacks Equity Research
Merck (MRK) beats estimates for earnings as well as sales in fourth-quarter 2018. Blockbuster cancer drug, Keytruda continues its robust performance on strong demand trends.
Pharma Stock Roundup: Q4 Earnings, Pipeline Updates at PFE, RHHBY
by Zacks Equity Research
Pfizer (PFE), Allergan (AGN), AbbVie (ABBV) and Novartis (NVS) report Q4 results.
J&J's Erleada Meets Both Primary Endpoints in Late-Stage Study
by Zacks Equity Research
Johnson & Johnson's (JNJ) Erleada improves survival in metastatic castration-sensitive prostate cancer study.
Roche Halts Two Late-Stage Studies on Alzheimer's Candidate
by Zacks Equity Research
Roche (RHHBY) discontinues two phase III studies evaluating its anti-beta-amyloid molecule, crenezumab in people with early sporadic Alzheimer's disease.
Biogen (BIIB) Q4 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
Biogen (BIIB) beats estimates for both earnings and sales in the fourth quarter of 2018, driven by higher sales of Spinraza.
The Zacks Analyst Blog Highlights: Johnson & Johnson, Boeing, Starbucks, Norfolk and Prologis
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Johnson & Johnson, Boeing, Starbucks, Norfolk and Prologis
Pfizer (PFE) Q4 Earnings Beat, 2019 View Tepid, Stock Dips
by Zacks Equity Research
Pfizer's (PFE) fourth-quarter earnings and sales beat estimates. Its forecast for 2019 falls short of expectations. Stock dips 2% in pre-market trading.